In this in-depth walkthrough, Grayson introduces the brand-new Market Summary Dashboard, an all-in-one resource designed to help you analyze the market with ease, speed,...
Earnings season continues, and this week we’re looking at three companies heading into their reports with different trajectories. One is in a long-term downtrend,...
Amid ever-increasing uncertainties on the global front and similarly rising geopolitical tensions between India and Pakistan, the Indian equity markets demonstrated strong resilience. They...
The identity of a Trump administration official who was allegedly targeted by the Biden administration’s State Department in a ‘disinformation’ dossier remains a mystery...
Hell hath now frozen over. President Donald Trump’s decision to accept a $400-million plane from Qatar, as a gift, has prompted stinging criticism from...
Last week, the broader market Indices hit another new high on Thursday before pulling back into Friday’s close. Not all areas participated, however, as...
In this edition of StockCharts TV‘s The Final Bar, Dave answers viewer questions on using technical indicators on leveraged and inverse ETFs like SOXL and SOXS,...
In this edition of StockCharts TV‘s The Final Bar, Dave recaps a day where technology shares struggles, with leading names like NVDA and MU dropping bearish...
Editor’s Note: This article was originally published on November 21, 2022. This article has absolutely nothing to do with trend following or the markets....
Gilead Sciences’ (GILD) new HIV prevention shot, lenacapavir, hit it out of the park in a late-stage trial, showing 100% effectiveness. 2,000 women participated...